Status:
RECRUITING
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Lung Cancer, Nonsmall Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.
Eligibility Criteria
Inclusion
- Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
- Prior exposure to at least 1 line of therapy
- Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial
- ECOG PS 0-2
Exclusion
- Presence of a driver mutation that is susceptible to targeted therapy
- No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy
- Other active invasive malignancy requiring ongoing therapy
- Evidence of progressing or untreated brain metastases
- Evidence or history of leptomeningeal disease
- Uncontrolled tumor related pain
- History of an autoimmune disease or IPF
Key Trial Info
Start Date :
July 25 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2027
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT04691817
Start Date
July 25 2023
End Date
September 1 2027
Last Update
January 7 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104